Nurix Therapeutics, Inc.: Vestal Point Capital, LP amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Vestal Point Capital, LP amended its Schedule 13G filing on Nurix Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0000902664-26-004581. The filing, submitted via SEC filer 0000902664, revises the investment firm's previously reported position in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically filed by passive investors to reflect changes in holdings above the 5% threshold or to update prior disclosures. The exact revised share count and percentage were not detailed in the filing summary. Investors will watch for further 13G/13D updates to gauge institutional conviction in Nurix, alongside the company's upcoming clinical and financial disclosures.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Nurix Therapeutics, Inc., Vestal Point Capital, LP